Literature DB >> 12195688

The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.

Nejma Ameziane1, Cendrine Seguin, Delphine Borgel, Frédéric Fumeron, Didier Moatti, Martine Alhenc-Gelas, Bernard Grandchamp, Martine Aiach, Joseph Emmerich, Dominique de Prost.   

Abstract

We have previously identified, in intron 7 of the TFPI gene, a T to C single-base polymorphism (-33T-->C) which is strongly associated with total circulating TFPI antigen levels. Here we examined the influence of this polymorphism on the risk of venous thromboembolism. The polymorphism was identified in the PATHROS study population (330 cases with venous thromboembolism and 826 controls). The CC genotype was found in 6.4% of cases and 10.2% of controls (age-adjusted odds ratio 0.6; 95% CI 0.3-0.9; p = 0.03). This protective effect persisted after adjustment for oral contraception and the factor V Leiden and prothrombin gene polymorphisms. In 171 controls and 49 cases in whom blood was taken at least three months after the thrombotic event, the CC genotype was associated with significantly higher total TFPI levels than the TT genotype. These results suggest that the CC genotype of the TFPI intron 7 polymorphism is an independent protective factor for venous thromboembolism, an effect probably mediated by increased TFPI levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195688

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Genetic susceptibility to thrombosis.

Authors:  James P Luyendyk; Rachel E Tilley; Nigel Mackman
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

2.  Investigation on genetic thrombophilic factors in FFPE autopsy tissue from subjects who died from pulmonary embolism.

Authors:  Francesco Brandimarti; Federica Alessandrini; Mauro Pesaresi; Chiara Catalani; Letizia De Angelis; Roberta Galeazzi; Simona Giovagnetti; Rosaria Gesuita; Elisa Righi; Raffaele Giorgetti; Adriano Tagliabracci
Journal:  Int J Legal Med       Date:  2016-12-09       Impact factor: 2.686

3.  Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Authors:  Mari Tinholt; Hans Kristian Moen Vollan; Kristine Kleivi Sahlberg; Sandra Jernström; Fatemeh Kaveh; Ole Christian Lingjærde; Rolf Kåresen; Torill Sauer; Vessela Kristensen; Anne-Lise Børresen-Dale; Per Morten Sandset; Nina Iversen
Journal:  Breast Cancer Res       Date:  2015-03-26       Impact factor: 6.466

4.  Association of TFPI polymorphisms rs8176592, rs10931292, and rs10153820 with venous thrombosis: A meta-analysis.

Authors:  Yunhong Zhang; Aimei Pang; Lin Zhao; Qiang Guo; Zhen Zhang; Xiaoxiao Zhu; Ran Wei; Xunqiang Yin; Bin Wang; Xia Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.